naproxen has been researched along with febuxostat in 5 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 818 | 133 | 710 |
| Protein | Taxonomy | naproxen (IC50) | febuxostat (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1.9 | |
| Albumin | Homo sapiens (human) | 0.0013 | |
| Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | Rattus norvegicus (Norway rat) | 0.004 | |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | 0.0164 | |
| Nuclear receptor ROR-gamma | Mus musculus (house mouse) | 0.025 | |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | 0.0166 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.03 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A | 1 |
1 review(s) available for naproxen and febuxostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for naproxen and febuxostat
| Article | Year |
|---|---|
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cross-Over Studies; Drug Interactions; Febuxostat; Female; Gout Suppressants; Humans; Indomethacin; Male; Metabolic Clearance Rate; Middle Aged; Naproxen; Reference Values; Thiazoles | 2006 |
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delayed-Action Preparations; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; gamma-Glutamyltransferase; Glomerular Filtration Rate; Gout; Gout Suppressants; Headache; Humans; Hypertension; Male; Middle Aged; Naproxen; Nasopharyngitis; Renal Insufficiency, Chronic; Respiratory Tract Infections; Severity of Illness Index; Treatment Outcome; Uric Acid | 2019 |
2 other study(ies) available for naproxen and febuxostat
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |